Company Overview: Isoray

Industry News

10 May

IsoRay Announces Third Quarter Fiscal 2017 Financial Results

RICHLAND, Wash., May 10, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced financial results for the third quarter of fiscal 2017, ended March...

Read more

3 May

IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”

RICHLAND, Wash., May 3, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the acceptance for publication of a study entitled “Long-term...

Read more

18 Apr

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

NEW YORK, NY / ACCESSWIRE / April 18, 2017 / IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that it will be presenting at...

Read more

8 Feb

IsoRay Announces Second Quarter Fiscal 2017 Financial Results

RICHLAND, Wash., Feb. 8, 2017 /PRNewswire/ –­­ IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced financial results for the second quarter of fiscal 2017, ended December...

Read more

7 Feb

MicroCap Review Magazine Winter/Spring 2017 Issue Now Available

LOS ANGELES, Feb. 7, 2017 /PRNewswire/ — SNN Incorporated, a global multimedia financial news and publishing company focused on the MicroCap stock market, and publisher of the MicroCap Review Magazine, is pleased to announce the release of the MicroCap Review Magazine Winter/Spring 2017 issue online and in print. The Winter/Spring...

Read more

21 Dec

IsoRay, Inc. Announces the Launch of a Pilot Study Using Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Resectable High Risk Recurrent Head and Neck Cancer by Case Comprehensive Cancer Center

RICHLAND, Wash., Dec. 21, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of a pilot study investigating the role of...

Read more

30 Nov

IsoRay to Present at 9th Annual LD Micro Investor Conference

RICHLAND, Wash., Nov. 30, 2016 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that Tom LaVoy, Chairman and CEO, and Brien Ragle,...

Read more

29 Nov

IsoRay Announces “Cesium-131 Brachytherapy for Salvage of Recurrent High Grade Glioma” Poster Presentation at 21st Annual Scientific Meeting of Society for Neuro-Oncology

RICHLAND, Wash., Nov. 29, 2016 /PRNewswire/ –­­ IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in Cesium-131 seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced a poster presentation at the 21st Annual Meeting...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address